Seidman A D, Reichman B S, Crown J P, Yao T J, Heelan R, Hakes T B, Lebwohl D E, Gilewski T A, Surbone A, Currie V
Memorial Sloan-Kettering Cancer Center, New York 10021.
J Natl Cancer Inst Monogr. 1993(15):171-5.
Twenty-eight patients received Taxol as their first chemotherapy for stage IV breast cancer. An additional 51 patients with extensive prior exposure to other chemotherapeutic agents received Taxol as salvage therapy. We found significant activity for the drug in both situations, as well as a strong clinical suggestion of non-cross-resistance with doxorubicin. An excellent response in previously irradiated skin was noted in one case. The routine use of recombinant human granulocyte-colony stimulating factor seemed to ameliorate some of the dose-limiting toxicity of neutropenia. Other toxicity was mild to moderate in most cases. With further development, Taxol should play a significant role in the systemic management of breast cancer.
28例IV期乳腺癌患者接受紫杉醇作为其一线化疗药物。另外51例曾广泛接触过其他化疗药物的患者接受紫杉醇作为挽救治疗。我们发现该药物在这两种情况下均具有显著活性，并且有强有力的临床证据表明其与阿霉素不存在交叉耐药性。有1例患者之前接受过放疗的皮肤出现了极佳的反应。重组人粒细胞集落刺激因子的常规使用似乎减轻了一些中性粒细胞减少的剂量限制性毒性。在大多数情况下，其他毒性为轻度至中度。随着进一步研发，紫杉醇在乳腺癌的全身治疗中应会发挥重要作用。
